Seaport Therapeutics Starts Phase 2a Trial of GlyphAgo in GAD
Seaport Therapeutics dosed the first patient in a six-week Phase 2a trial of GlyphAgo (SPT-320) in adults with GAD and sleep disturbance in Australia.
Seaport Therapeutics dosed the first patient in a six-week Phase 2a trial of GlyphAgo (SPT-320) in adults with GAD and sleep disturbance in Australia.